Key Developments: DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

28.41EUR
22 Oct 2014
Price Change (% chg)

€0.20 (+0.71%)
Prev Close
€28.21
Open
€28.42
Day's High
€28.58
Day's Low
€28.25
Volume
39,576
Avg. Vol
38,094
52-wk High
€39.22
52-wk Low
€26.00

Search Stocks

Latest Key Developments (Source: Significant Developments)

DiaSorin SpA announces launch of new LIAISON HIV HT; wins tender with the Red Crescent in Turkey
Tuesday, 7 Oct 2014 03:31am EDT 

DiaSorin SpA:Announces the launch of the new test LIAISON XL murex HIV Ab/Ag High Throughput (HT) outside the USA and Canada.Says in recent weeks, DiaSorin has won a tender with the Red Crescent in Turkey, confirming the appreciation for DiaSorin’s solutions by Blood Banks.Says the launch of the new test LIAISON XL murex HIV Ab / Ag high-throughput (HT) enhances the offer and competitiveness of DiaSorin for the Blood Banks of medium and large size.  Full Article

DiaSorin SpA launches sixth LIAISON test for qualitative detection of Adenovirus
Thursday, 18 Sep 2014 11:09am EDT 

DiaSorin SpA:Says it launched, in markets outside the United States and the United Kingdom, its sixth LIAISON test for the qualitative detection of Adenovirus in stool samples.The test is an addition to the 5 important tests of the stool testing panel, already available on the market (C. Difficile toxin A&B, C. Difficile GDH, Helicobacter Pylori, EHEC, Rotavirus).Says Adenovirus is a virus that is resistant to drugs and dangerous for infants, children and immunosuppressed patients and is, along with Rotavirus, spread-out worldwide.  Full Article

DiaSorin SpA launches molecular diagnostic test for herpes simplex virus types 1 and 2
Monday, 30 Jun 2014 08:46am EDT 

DiaSorin SpA:Announces the launch of its sixth molecular diagnostic test on its LIAISON IAM platform for the detection of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) on plasma and serum samples.Says the Herpes Simplex Virus (HSV), often contracted in early childhood, is contagious, usually not recognized by the patient and is latent after infection and can reactivate periodically.Says, when infections are symptomatic, typically involve oral lesions that heal within 2-3 weeks or genital lesions.Says the new DiaSorin IAM HSV test is available on the market outside of the United States and Canada.Says it adds on to the existing molecular diagnostics offer of the Group made of BK Virus (IAM BKV), Varicella Zoster Virus (IAM VZV), Toxoplasmosis (IAM TOXO), Parvovirus (IAM PARVO) and Cytomegalovirus (IAM CMV).  Full Article

DiaSorin SpA launches Vitamin D 1.25 on LIAISON XL-Reuters
Monday, 2 Jun 2014 08:00pm EDT 

DiaSorin SpA:Launches its new 1.25 Vitamin D assay for the quantitative determination of 1.25 Dihydroxyvitamin D levels in human serum and plasma, available on the LIAISON XL analyzer for the market outside the U.S. only-Reuters.  Full Article

DiaSorin SpA confirms FY 2014 guidance
Friday, 9 May 2014 07:52am EDT 

DiaSorin SpA:Confirms the FY 2014 guidance already announced.Expects revenues to grow between 3 and 5 pct at CER compared with 2013.Expects EBITDA to grow equal to about 3 pct at CER compared with 2013.FY 2014 revenues at 452.96 mln euros (2013: 434.85 mln euros)-Thomson Reuters I/B/E/S.  Full Article

DiaSorin SpA announces 0.55 euros per share dividend for FY 2013; issues FY 2014 revenues and EBITDA guidance
Thursday, 6 Mar 2014 08:19am EST 

DiaSorin SpA:Says the Board approved the motion for the allocation of the net profit for fiscal year 2013, including the payment of a gross dividend of 29,919,041.35 euros, equal to 0.55 euros per share, with the exception of treasury shares.Ex-dividend on May 19, record date on May 21 and payment on May 22.Sees for fiscal year 2014 revenues growth between 3 pct and 5 pct at CER compared with 2013.Sees fiscal year 2014 EBITDA growth equal to ca. 3 pct at CER compared with 2013.  Full Article

DiaSorin SpA launches new N-TACT PTH Gen II on LIAISON platform
Tuesday, 18 Feb 2014 07:01am EST 

DiaSorin SpA:Says it launched a new product in its portfolio, the LIAISON N-TACT PTH Gen II assay, for the quantitative determination of intact human parathyroid hormone (PTH) in human serum and plasma.Says the LIAISON N-TACT PTH Gen II assay is a redevelopment of the existing N-TACT PTH assays and employs specific polyclonal antibodies to assist in diagnosis of disorders of calcium metabolism.Says this assay is an addition to the current DiaSorin LIAISON Bone and Mineral menu made of both specialty and main stream tests such as the 25-OH Vitamin D TOTAL Assay, 1-84 PTH, BAP OSTASE and Osteocalcin.  Full Article

DiaSorin SpA launches the Rotavirus test on LIAISON stool sample
Tuesday, 11 Feb 2014 05:48am EST 

DiaSorin SpA:Says it launched the LIAISON Rotavirus test for the qualitative detection of Rotavirus in stool specimens, available in the market outside the US and UK only.Says the new LIAISON Rotavirus is the fifth test launched on the LIAISON Stool menu, in addition to the other tests already on the market (C. difficile Toxin AB, C. Difficile GDH, H. pylori, EHEC) since 2013.Says DiaSorin's LIAISON solution aims at improving the way Rotavirus test is performed to date.  Full Article

DiaSorin SpA extends its relationship with Laboratory Corporation of America Holdings
Tuesday, 28 Jan 2014 04:41am EST 

DiaSorin SpA:Says it has signed a 3 year extension of its master agreement, through the end of 2018, with Laboratory Corporation of America Holdings (LabCorp).Says the purpose of the agreement extension is to expand DiaSorin’s LIAISON XL menu offering to LabCorp, while maintaining the existing Vitamin D business.Says DiaSorin will add 15 new assays to the current menu for LabCorp, which will expand its offering of DiaSorin tests in new clinical areas.  Full Article

DiaSorin SpA obtains approval of hepatitis, retrovirus and syphilis tests on Liaison XL platform in China
Friday, 24 Jan 2014 02:41am EST 

DiaSorin SpA:Announces the obtainment of all the marketing approvals for Hepatitis, Retroviral and Syphilis assays on its LIAISON XL platform for the Chinese market.Says new tests include the complete panel of hepatitis B, hepatitis C, HIV and Treponema Assays.  Full Article

Diasorin confirms 2014 guidance after Q1 core earnings fall

MILAN, May 9 - Italian medical diagnostics group Diasorin confirmed its full-year guidance on Friday after posting a 7.2 percent fall in core earnings in the first quarter.

Search Stocks